Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial

Journal of Affective Disorders

Volumn 185, Issue , 2015, Pages 209-213

  Brunoni, André R ^a   Machado Vieira, Rodrigo ^b   Sampaio Junior, Bernardo ^a   Vieira, Erica L M ^c   Valiengo, Leandro ^a   Benseñor, Isabela M ^a   Lotufo, Paulo A ^a   Carvalho, André F ^d   Cho, Hyong Jin ^e   Gattaz, Wagner F ^a   Teixeira, Antonio L ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Major depressive disorder; Sertraline; STNFR1; STNFR2; Transcranial direct current stimulation

Indexed keywords

PLACEBO; SERTRALINE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTIDEPRESSANT AGENT;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NERVE STIMULATOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSCRANIAL DIRECT CURRENT STIMULATION; TREATMENT RESPONSE; BLOOD; CONTROLLED CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SERTRALINE; TRANSCRANIAL DIRECT CURRENT STIMULATION; TREATMENT OUTCOME;

EID: 84938319315     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2015.07.006     Document Type: Article

References (23)

1. A.R. Brunoni, A.H. Kemp, E.M. Dantas, A.C. GOulart, M.A. Nunes, P.S. Boggio, J.G. Mill, P.A. Lotufo, F. Fregni, and I.M. Bensenor Heart rate variability is a trait marker of major depressive disorder: Evidence from the Sertraline vs. Electric Current Therapy to Treat Depression Clinical Study Int. J. Neuropsychopharmacol. 2013 (Epub ahead of print)
2. A.R. Brunoni, R. Machado-Vieira, C.A. Zarate Jr., E.L. Vieira, L. Valiengo, I.M. Bensenor, P.A. Lotufo, W.F. Gattaz, and A.L. Teixeira Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis Prog. Neuropsychopharmacol. Biol. Psychiatry 56C 2014 91 96
3. A.R. Brunoni, R. Machado-Vieira, C.A. Zarate Jr., E.L. Vieira, M.A. Vanderhasselt, M.A. Nitsche, L. Valiengo, I.M. Bensenor, P.A. Lotufo, W.F. Gattaz, and A.L. Teixeira BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial, randomized, sham-controlled trial Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 24 2014 1144 1151
4. A.R. Brunoni, R. Machado-Vieira, C.A. Zarate, L. Valiengo, E.L. Vieira, I.M. Bensenor, P.A. Lotufo, W.F. Gattaz, and A.L. Teixeira Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial Psychopharmacology 231 2014 1315 1323
5. A.R. Brunoni, L. Valiengo, A. Baccaro, T.A. Zanao, J.F. de Oliveira, G.P. Vieira, V.F. Bueno, A.C. Goulart, P.S. Boggio, P.A. Lotufo, I.M. Bensenor, and F. Fregni Sertraline vs. ELectrical Current Therapy for Treating Depression Clinical Trial - SELECT TDCS: design, rationale and objectives Contemp. Clin. Trials 32 2011 90 98
6. A.R. Brunoni, L. Valiengo, A. Baccaro, T.A. Zanao, A.C. Oliveira, A.C. Goulart, P.S. Boggio, P.A. Lotufo, I.J. Bensenor, and F. Fregni The sertraline versus electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial JAMA Psychiatry 70 2013 383 391
7. B. Dean, A.S. Gibbons, N. Tawadros, L. Brooks, I.P. Everall, and E. Scarr Different changes in cortical tumor necrosis factor-alpha-related pathways in schizophrenia and mood disorders Mol. Psychiatry 18 2013 767 773
8. N. DellaGioia, and J. Hannestad A critical review of human endotoxin administration as an experimental paradigm of depression Neurosci. Biobehav. Rev. 34 2010 130 143
9. M. Fornaro, G. Rocchi, A. Escelsior, P. Contini, and M. Martino Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds J. Affect. Disord. 145 2013 300 307
10. R. Grassi-Oliveira, E. Brietzke, J.C. Pezzi, R.P. Lopes, A.L. Teixeira, and M.E. Bauer Increased soluble tumor necrosis factor-alpha receptors in patients with major depressive disorder Psychiatry Clin. Neurosci. 63 2009 202 208
11. J. Hannestad, N. DellaGioia, and M. Bloch The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 36 2011 2452 2459
12. M.B. Howren, D.M. Lamkin, and J. Suls Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis Psychosom. Med. 71 2009 171 186
13. O. Kohler, M.E. Benros, M. Nordentoft, M.E. Farkouh, R.L. Iyengar, O. Mors, and J. Krogh Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry 71 2014 1381 1391
14. S. Lanquillon, J.C. Krieg, U. Bening-Abu-Shach, and H. Vedder Cytokine production and treatment response in major depressive disorder Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 22 2000 370 379
15. M. Maes, P. Ruckoanich, Y.S. Chang, N. Mahanonda, and M. Berk Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 769 783
16. N. Muller, and M.J. Schwarz The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression Mol. Psychiatry 12 2007 988 1000
17. A. Munzer, U. Sack, R. Mergl, J. Schonherr, C. Petersein, S. Bartsch, K.C. Kirkby, K. Bauer, and H. Himmerich Impact of antidepressants on cytokine production of depressed patients in vitro Toxins 5 2013 2227 2240
18. C.L. Raison, R.E. Rutherford, B.J. Woolwine, C. Shuo, P. Schettler, D.F. Drake, E. Haroon, and A.H. Miller A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatry 70 2013 31 41
19. A.L. Teixeira, R.T. de Souza, M.V. Zanetti, A.R. Brunoni, G.F. Busatto, C.A. Zarate Jr., W.F. Gattaz, and R. Machado-Vieira Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment Hum. Psychopharmacol. 30 2015 52 56
20. V. Valkanova, K.P. Ebmeier, and C.L. Allan CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies J. Affect. Disord. 150 2013 736 744
21. H. Wajant, K. Pfizenmaier, and P. Scheurich Tumor necrosis factor signaling Cell. Death Differ. 10 2003 45 65
22. Z. Xia, J.W. DePierre, and L. Nassberger Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells Immunopharmacology 34 1996 27 37
23. J.J. Young, D. Bruno, and N. Pomara A review of the relationship between proinflammatory cytokines and major depressive disorder J. Affect. Disord. 169 2014 15 20